2-Substituted agelasine analogs : synthesis and biological activity, and structure and reactivity of synthetic intermediates by Roggen, Heidi et al.
645
Pure Appl. Chem., Vol. 83, No. 3, pp. 645–653, 2011.
doi:10.1351/PAC-CON-10-09-25
© 2011 IUPAC, Publication date (Web): 25 January 2011
2-Substituted agelasine analogs: Synthesis and
biological activity, and structure and reactivity
of synthetic intermediates*
Heidi Roggen1,‡, Lars Bohlin2, Robert Burman2, Colin Charnock3,
Jenny Felth2, Carl Henrik Görbitz1, Rolf Larsson2, Toomas Tamm4,
and Lise-Lotte Gundersen1
1Department of Chemistry, University of Oslo, P.O. Box 1033 Blindern,
N-0315 Oslo, Norway; 2Department of Medicinal Chemistry, Biomedical Centre,
Uppsala University, Box 574, SE-751 23 Uppsala, Sweden; 3Faculty of Health
Sciences, Oslo University College, P.O. Box 4 St. Olavs Plass, N-0130 Oslo,
Norway; 4Tallinn University of Technology, Ehitajate tee 5, EE-19086 Tallinn,
Estonia
Abstract: 2-Substituted N-methoxy-9-methyl-9H-purin-6-amines were synthesized either
from their corresponding 6-chloro-9-methyl-9H-purines or 2-chloro-N-methoxy-9-methyl-
9H-purin-6-amine. Great diversity in the amino/imino tautomeric ratios was observed and
calculated based on 1H NMR. The tautomers were identified by 1D and 2D 1H, 13C, and
15N NMR techniques, and showed significant variation both in 13C and 15N shift values.
Comparison of the tautomeric ratios with Hammett F values revealed that as the field/induc-
tive withdrawing abilities of the 2-substituent increased, the ratio of amino:imino tautomers
was shifted toward the amino tautomer. Computational chemistry exposed the significance of
hydrogen bonding between solvent and the compound in question to reach accurate predic-
tions for tautomeric ratios. B3LYP/def2-TZVP density functional theory (DFT) calculations
resulted in quantitatively more accurate predictions than when employing the less expensive
BP86 functional. N-7-Alkylation of the 2-substituted N-methoxy-9-methyl-9H-purin-6-
amines showed that when the field/inductive withdrawing ability of the 2-substituent reached
a certain point the reactivity drastically dropped. This correlated with the atomic charges on
N-7 calculated using a natural bond orbital (NBO) analysis. Biological screening of the final
2-substituted agelasine analogs indicated that the introduction of a methyl group in the
2-position is advantageous for antimycobacterial and antiprotozoal activity, and that an
amino function may improve activity against several cancer cell lines.
Keywords: agelasine; biological activity; density functional theory; purine; tautomerism;
X-ray crystallography.
INTRODUCTION
Natural products are an important source for new drugs, either as the active component, or as inspira-
tion [1]. Since the 1970s, a group of purine compounds called agelasines (Fig. 1) have been isolated
*Paper based on a presentation made at the 18th International Conference on Organic Synthesis (ICOS-18), Bergen, Norway, 1–6
August 2010. Other presentations are published in this issue, pp. 411–731.
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from marine sponges (Agelas sp.) [1–3]. They have shown bioactivities such as antifouling activity,
cytotoxic effects, and antimicrobial activity, amongst others against Mycobacterium tuberculosis, the
main cause of tuberculosis in humans [1].
Previously, we have reported the total synthesis of agelasines D [4] and E [5], and a range of age-
lasine analogs with variation in substituents on N6, N-7, and N-9 of the purine scaffold [6]. We would
now like to give a short review on our recently reported work related to 2-substituted agelasine analogs,
and the structure and reactivity of certain interesting synthetic intermediates [7–9].
As trisubstituted purines, agelasines require regioselective syntheses. Unfortunately, alkylation of
a 9-substituted adenine gives mainly N-1- or N6-alkylation [10,11]. Inversing the introduction of the
7- and 9-substituents does not help, because a 7-substituted adenine will most likely be alkylated on N-3
(see Fig. 1 for numbering of the purine ring system) [12]. However, introducing an alkoxy group on N6
of a 9-substituted purine results mainly in the desired 7-alkylation, and the alkoxy group can be
removed after the alkylation. To date, all agelasines and analogs have been prepared by this method
[13,14].
SYNTHESIS
The substituents on N6, N-7, and N-9 for the target 2-substituted agelasine analogs (4) were chosen
based on previous studies to achieve high bioactivity [4,5,10]. Nine N-methoxy-9-methyl-9H-purin-6-
amines (2) were then prepared as intermediates for the synthesis of a series of 2-substituted agelasine
analogs (3) (Scheme 1). Preparation of these synthetic intermediates was achieved either by introduc-
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Fig. 1 General structure of agelasines (left) and examples of substituents R (right) of three naturally occurring
agelasines.
Scheme 1 General synthetic route to compounds 2, 3, and 4, and substituents R used in the study.
tion of a methoxyamino group on C-6 from corresponding 2-substituted 6-chloro-9-methyl-9H-purines
(1) or by nucleophilic aromatic substitution on C-2 of the 2-chloro-N-methoxy-9-methyl-9H-purin-6-
amines (2h) [7].
To study the reactivity of the synthetic intermediates 2 in alkylation reactions, compounds 2a–i
were treated with benzyl bromide in DMA at 50 °C for 25 h (Scheme 1, Table 1). The reactions resulted
in the expected N-7- and N6-alkylated products in most cases, with the former as the major product, but
also revealed a significant variation in reactivity for the nine analogs. Benzylation of the methoxy com-
pound 2f resulted in the formation of a range of products; the O2-methyl group appeared to be unstable
under the reaction conditions either in starting material 2f and/or product 3f [7]. Demethylation of other
methoxypurines has previously been observed in the Gundersen research group at the University of
Oslo [15]. 2-Ethoxypurine 2e showed no detectable cleavage of the alkoxy group. A comparison of the
field/inductive withdrawing ability (Hammett F values were employed) of the 2-substituents with the
reactivity of the compounds was then conducted. Compounds 2 with substituents with Hammett F val-
ues lower than approximately 0.3 displayed good reactivity toward N-7-alkylation, whereas Hammett F
values higher than this resulted in very low or no formation of the desired compounds 3 [7].
Table 1 Field/inductive parameter (F) for the substituents R, calculated and experimental tautomeric ratios of the
compounds 2, calculated NBO atomic charges on N-7 in the amino tautomers 2, and isolated yields from
N-7-alkylation of compounds 2 by treatment with R'Br.
Compound R Fa % Amino tautomer NBO % Yield from 2
Single molecule DMSO H-bonded NMRb atomic
complex charge
BP/ BP86/ B3LYP/ BP86/ B3LYP/ on N7c
SV(P) def2-TZVP def2-TZVP def2-TZVP def2-TZVP
2a H 0.03 5 2 13 9 30 20 –0.481 3a: 51 4a: 49
2b Me 0.01 2 0 2 2 7 18 –0.488 b: 57 4b: 44
2c NHMe 0.03 39 10 36 1 2 28 –0.487 33c: 56 4c: 42
2d NMe2 0.15 76 21 55 88 98 100 –0.479 3d: 61 4d: 26
2e OEt 0.26 30 21 55 90 96 94 –0.483 3e: 52 4e: 39
2f OMe 0.29 28 19 42 69 86 92 n.d.d 3f: –e 4j: 55g,i
2g CF3 0.38 96 95 95 100 100 100 –0.476 3g: <2f 4g: n.d.d
2h Cl 0.42 97 91 91 100 100 100 –0.473 3h: 4g 4h: 18
2i NO2 0.65 96 90 90 100 100 100 –0.473 3i: n.o.h 4i: n.d.d
aTaken from ref. [16]. 
bDetermined by 1H NMR data obtained in DMSO-d6 at 25 °C. 
cFor amino tautomers 2. Based on the B3LYP/def2-TZVP calculations in solution phase where hydrogen bonding is included.
Similar results were seen when results from BP86/def2-TZVP calculations were used, and also when no hydrogen bonding to a
solvent molecule was included.
dNot determined.
eFormed, but not isolated in pure form.
fCalculated from 1H NMR of a mixture.
gIsolated as betaine.
hNot observed (n.o.).
iR = OH
To determine the atomic charges on N-7 (which should function as the nucleophile in the alkyla-
tion of compounds 2), a partial natural bond orbital (NBO) analysis [17] was performed (Table 1) as a
part of a computation study of the compounds 2 [9]. The results indicated that a minimum negative
charge was required on N-7 for the alkylation to occur. If this negative charge was too low, poor yields
were observed.
The chloro analog 2h was then treated with geranylgeranyl bromide, in DMA at 50 °C for 25 h
to prepare its corresponding N-7-alkylated agelasine analog. An increase in reactivity from 4 to 18 %
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was observed compared with the test reaction using benzyl bromide as the alkylating agent (Scheme 1,
Table 1). Although this yield was a significant improvement, it is still a poor yield, and the two other
low-yielding synthetic intermediates 2g,i were excluded in the agelasine analog synthesis. The remain-
ing six compounds 2a–f were treated with geranylgeranyl bromide in the same manner as compound
2h. Agelasine analogs 4 were isolated in low to acceptable yields, and the undesired  N6-alkylated prod-
ucts were isolated in lesser amounts in all reactions. As for the benzylation of compound 2j, the treat-
ment with geranylgeranyl bromide caused demethylation of the 2-methoxy group; the 2-oxo compound
was isolated in 55 % yield. With the highest isolated yield in the series, the demethylation appeared to
be quite facile [8].
STRUCTURE ANALYSES OF N-METHOXY-9-METHYL-9H-PURIN-6-AMINES (2)
Structure elucidation
In 1987, Fuji et al. reported that N-methoxy-9-methyl-9H-purin-6-amine (2a) existed as a mixture of
two tautomers in DMSO-d6 solution with its NH hydrogen on either N-1 or N6, as shown in Fig. 2 [18].
During the synthesis of 2-substituted N-methoxy-9-methyl-9H-purin-6-amines 2, we discovered that
these synthetic intermediates showed great diversity in tautomeric ratios depending on the substituent
in the 2-position (Table 1) [7].
For the 2-substituted compounds 2, no couplings in 2D 1H-13C or 1H-15N NMR supported nor
contradicted whether the NH hydrogen was situated on N-1 or not, although chemical shifts indicated
similarity with the N1-protonated 2a'. Because of the uncertainty surrounding the protonation site, the
possibility of different placements of the NH hydrogen was tested by computational chemistry. Imino
tautomers of the methoxy compound 2k with their NH on either N-1, N-3, or N-7 were all checked
using the BP86 density functional and the def2-TZVP basis set. The N-3- and N-7-protonated imino
tautomers turned out to have 46 and 36 kJ/mol higher energy than the N1-protonated imino tautomer,
respectively. Imino tautomers with its NH hydrogen at either of these two sites therefore seemed
unlikely, and in subsequent work it was assumed that the NH is situated on N1 for all imino structures
[9].
A study of the NMR data acquired for compounds 2 revealed several interesting trends in chem-
ical shifts depending on the identity of the tautomer for the compounds. 1H NMR shift values for our
system varied a fair bit depending on the C-2 substituent, and were quite close for the two tautomers.
The 13C NMR shifts showed a much clearer trend; as was indicated for 1H NMR, lower shift values
were clearly observed for the imino tautomers compared with the amino tautomers. This trend was
especially clear for C-4, C-6, and OCH3 whose peaks for the amino tautomers appeared at 150–153,
155–156, and 63–64 ppm, respectively, but at 142–144, 141–142, and 61 ppm for the imino tautomers.
15N NMR shift values (extracted from 2D 1H-15N HSQC and HMBC spectra) showed a considerable
difference for N6 for the two tautomers, as expected based on the major difference in structure for these
nitrogens; one having sp3, the other sp2 hybridization. In the amino tautomers N6 resonated at ca.
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Fig. 2 Tautomerism of N-methoxy-9-methyl-9H-purin-6-amines 2.
–210 ppm, compared with ca. –95 ppm in imines (relative to MeNO2 at 0 ppm). The opposite was seen
for N-1 whose peaks appeared at –186 ppm for amines vs. –245 ppm for imines. These NMR results
indicated that 13C and 15N NMR may be used to determine the identity of the major tautomer in these
systems [7].
Tautomeric ratios
Tautomeric ratios for compounds 2 were calculated from 1H NMR, and are shown in Table 1 as a per-
centage of the amino tautomer 2 out of the total of amino tautomer 2 + imino tautomer 2'. 1H NMR
spectra for all compounds 2 were also acquired in CD3OD solution at 25 °C, and calculated tautomeric
ratios were consistent with the results from DMSO-d6 solution with only small variations. Comparing
the Hammett F values of the substituents in the study with the tautomeric ratio of compounds 2, the
compounds appeared to divide into two groups; all the compounds in the series with substituents with
a significant field/inductive withdrawing ability showed the tautomeric ratio being shifted toward the
amino tautomer. For the substituents with a small field/inductive withdrawing ability on the other hand,
the imino tautomer dominated [7].
The experimental findings were backed up by a computational study. Accurately predicting the
tautomeric ratio of a chemical compound is considered a challenge for contemporary quantum chem-
istry [19]. Our approach to prediction of tautomeric equilibria was based on quantum-chemical com-
putation of the energy differences between the relevant tautomeric forms. These energy differences
were then used in the standard Boltzmann distribution formula to predict the tautomeric ratios [9].
Initial density functional theory (DFT) calculations using the low-cost functional BP86 with the
SV(P) basis set and a continuum solvation model predicted the correct major tautomer for only seven
out of nine compounds (Table 1). In addition, the quantitative predictions for the seven qualitatively cor-
rectly predicted compounds were far from the experimental observations. The imino tautomers
appeared to be predicted too stable compared to the amino tautomers, relative to what was observed
experimentally. Re-optimizing the geometries with a larger basis set def2-TZVP resulted in an addi-
tional compound being wrongly predicted (Table 1). The necessity of inclusion of continuum solvation
effects, zero-point vibrational energy and/or thermal corrections to the total energy was also checked,
and their utility confirmed for accurate predictions. Switching to the B3LYP functional, still employing
the def2-TZVP basis set, the predicted tautomeric ratios were somewhat improved, but the methoxy
compound 2f was still predicted as the imino tautomer, in addition to qualitative predictions being far
from the experimentally observed results (Table 1) [9].
Hydrogen bonding to the solvent, DMSO, may be responsible for the discrepancy between the
calculated and observed tautomeric ratios. 1H NMR of compound 2e was acquired in six different sol-
vents. The results showed that as the dipole moment of the solvent increased, the amount of amino
tauto mer also increased (Table 2). Furthermore, the percent amino tautomer was much higher in sol-
vents that can take part in hydrogen bonding compared with in those that can not. This indicated that
the amino tautomers were somehow stabilized by hydrogen bonds to the solvent. Hydrogen bonding
between the compound in question and the solvent, but also the polarity of the solvent, therefore seemed
essential for the tautomeric ratio [9].
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Table 2 Dipole moment of six solvents, their hydrogen bond acceptor abilities and the
amount of amino tautomer of compound 2e in each solvent determined by 1H NMR.
Solvent Dipole moment [20]a Hydrogen bond acceptor % Amino tautomer
Benzene-d6 0.07b No 13
CDCl3 1.08c No 24
CD2Cl2 1.59c No 29
CD3OD 1.67c Yes 74
Acetone-d4 2.78c Yes 84
DMSO-d6 3.94d Yes 92
aFor nondeuterated species. 
bLiquid. 
cIn benzene. 
dGas. 
eDetermined by 1H NMR spectroscopy at 25 °C.
As a computational counterpart to these experimental results, a molecule of DMSO was added
into the model. The hydrogen-bonded complexes were calculated using B3LYP/def2-TZVP. The inclu-
sion of an explicit DMSO molecule appeared to be significant in order to reach approximate quantita-
tive agreement with the experimentally observed tautomeric ratios. Both the BP86 and the B3LYP func-
tionals qualitatively predicted the correct dominating tautomer for all compounds; however, the B3LYP
results appeared quantitatively more accurate (Table 1), but with an at least threefold greater computa-
tional cost [9].
Molecular geometries
From calculations, the purine ring system was found to be essentially planar, with variation in orienta-
tion of the C-6 methoxyamino group, the N9 methyl group and in the C-2 substituent for both tauto -
meric forms of compounds 2. The methoxyamino group was found to have two distinct minima when
rotating around the C–N bond; the methoxy group was either directed toward N-1 in a syn orientation
(as shown in Scheme 1 and Fig. 2) or toward N-7 in an anti orientation [9]. Reported NMR [5,18,21]
and UV [18] studies of the imine 2a' and similar 6-methoxy amino purines have indicated that these
types of imines exist in this syn configuration in solution. According to our calculations, the imino
tauto mers all preferred the syn configuration regardless of the identity of the 2-substituent. For the
amino tautomers, the syn and anti conformations were much closer in energy, with energy differences
typically 2–5 kJ/mol depending on the computational model and the identity of the 2-substituent, com-
pared with typically 13–16 kJ/mol differences for the amino tautomers. Still, the syn conformation was
preferred for all amino tautomers in solution [9].
Single-crystal X-ray structures of nitro compound 2i (CCDC 789455) and methylamino com-
pound 2c (CCDC 789456) were acquired and indicated that these two compounds had crystallized as
their amino and imino tautomeric forms, respectively, the same as the major tautomers for each in
DMSO-d6 solution. The amino tauto mer of the nitro compound 2i showed formation of dimers located
on inversion centers, creating layers (Fig. 3, right). The imino tautomer of the methylamino compound
2c', on the other hand, was arranged in hydrogen-bonded chains (Fig. 3, left). Syn orientation of the
methoxyamino group was observed in both these crystals as predicted by calculations for the com-
pounds in solution [9].
H. ROGGEN et al.
© 2011, IUPAC Pure Appl. Chem., Vol. 83, No. 3, pp. 645–653, 2011
650
BIOLOGICAL ACTIVITY
All agelasine analogs 4 were screened for antimicrobial and antineoplastic activity [8]. All seven com-
pounds showed profound inhibition against M. tuberculosis (IC90 < 0.2–8.1 μg/mL). The 2-methyl ana-
log 4b is the most potent antimycobacterial agelasine analog identified to date (IC90 < 0.2 μg/mL), and
displayed an almost 10-fold improvement compared to the unsubstituted analog 4a. The remaining
2-substituted analogs were all slightly less active than compound 4a. These results may indicate that a
slightly larger group on C-2 is advantageous for activity against M. tuberculosis, but groups that sig-
nificantly differ from hydrogen in electronic properties show reduction in activity. 
Relatively good activities were observed against fungi C. krusei (MIC from 2 μg/mL) and C. albi-
cans (MIC from 2 μg/mL), protozoa P. falciparum (IC50 < 0.12–7.5 μg/mL), L. donovani (IC50 =
0.25–7.5 μg/mL), T. cruzi (IC50 < 0.12–0.91 μg/mL) and T. b. rhodesiense (IC50 < 0.12–0.94 μg/mL),
and gram-positive bacterium S. aureus (MIC = 4–16 μg/mL), for all the 2-substituted analogs. The
2-chloro analog 4h and the 2-hydroxy analog 4j generally showed lower activities than the other
analogs. All the compounds tested showed low activity against the gram-negative bacterium E. coli. 
Screening against a series of human cancer cell lines (U-937 GTB, RPMI 8226/s, CEM/s, and
ACHN), revealed that the amino analogs 4c,d showed similar or slightly improved activities compared
to the unsubstituted analog 4a in all cases (IC50 = 0.55–4.2 μg/mL). All other changes in the 2-position
resulted in lower anticancer activities. 
Unfortunately, the cytotoxicity against mammalian cells (VERO cells and/or MRC-5 fibroblasts)
was too high for any of the compounds to be of therapeutic use (IC50 = 0.45–13 μg/mL). 
CONCLUSION
Nine N-methoxy-9-methyl-9H-purin-6-amines (2) with various substituents in the purine 2 position
were synthesized either from their corresponding 6-chloro-9-methyl-9H-purines (1) or 2-chloro-N-
methoxy-9-methyl-9H-purin-6-amine (2h), and further treated with benzyl bromide in order to study
the reactivity of these compounds. Based on the study, seven of the synthetic intermediates 2 were then
treated with geranylgeranyl bromide, and the resulting 7-alkylated agelasine analogs (4) were screened
for various biological activities, including as antimicrobials and anticancer agents. The results indicated
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Fig. 3 X-ray crystal structure of methylamino compound 2c (left) and nitro compound 2i (right) with bond lengths
of covalent bonds. Intermolecular bonds to adjacent molecules are indicated by dotted lines.
that the introduction of a methyl group in the 2-position is advantageous for antimycobacterial and
antiprotozoal activity, and that an amino function may improve activity against several cancer cell lines.
NMR spectroscopy, computational chemistry, and X-ray crystallography were employed to describe the
structure of synthetic intermediates 2. DFT calculations using the B3LYP functional with the
def2-TZVP basis set with inclusion of hydrogen bonding to a solvent molecule (DMSO) resulted in the
highest quantitative correlation between calculated and experimental results. NBO analysis indicated
that the field/inductive withdrawing ability of the C-2 substituents influence the atomic charge on N-7.
One or both of these properties affect the reactivity of the compounds in 7-alkylation.
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